<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMCINONIDE- amcinonide cream </strong><br>E. Fougera &amp; Co. a division of Fougera Pharmaceuticals Inc.<br></p></div>
<h1>AMCINONIDE CREAM USP, 0.1%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>NOT FOR OPHTHALMIC USE.<br>FOR DERMATOLOGIC USE ONLY.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
</p>
<p>Each gram of Amcinonide Cream USP, 0.1% contains: 1 mg of active steroid Amcinonide, 
Benzyl Alcohol 2% (wt/wt) as preservative, Emulsifying Wax, Glycerin, 
Isopropyl Palmitate, Lactic Acid, Purified Water and Sorbitol Solution. 
Chemically, amcinonide is:
</p>
<div class="Figure">
<a name="f1"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8aefa477-ac2c-41c8-a807-d24522aed8f0&amp;name=amc03-0003-01.jpg">
</div>
<p>Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11β, 16α).
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Topical corticosteroids have anti-inflammatory, antipruritic and vasoconstrictive actions.
</p>
<p>The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pharmacokinetics:</span> The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
</p>
<p>Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see <span class="Bold"><a href="#s19">DOSAGE AND ADMINISTRATION</a></span>).
</p>
<p>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.
</p>
<p>Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Topical corticosteroids are contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold Italics">General:</span> Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and glucosuria in some patients.
</p>
<p>Conditions that augment systemic absorption include the application of the more potent 
steroids, use over large surface areas, prolonged use and the addition of occlusive dressings. 
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under 
an occlusive dressing should be evaluated periodically for evidence of HPA-axis suppression by using the urinary free-cortisol and ACTH stimulation tests.</p>
<p>
If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute with a less potent steroid.
</p>
<p>Recovery of HPA-axis function is generally prompt and complete upon discontinuation of the drug.
</p>
<p>Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
</p>
<p>Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see <span class="Bold"><a href="#s16">PRECAUTIONS-Pediatric Use</a></span>).
</p>
<p>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
</p>
<p>In the presence of dermatological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.
</p>
<p>The products are not for ophthalmic use.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s11"></a><a name="section-6.2"></a><p></p>
<p class="First"><span class="Bold Italics">Information for the Patient</span>: Patients using topical corticosteroids should receive the following information and instructions:
</p>
<ol class="Arabic">
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
</li>
<li>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped, as to be occlusive, unless directed by the physician.
</li>
<li>Patients should report any signs of local adverse reactions, especially those that occur under occlusive dressings.
</li>
<li>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s12"></a><a name="section-6.3"></a><p></p>
<p class="First"><span class="Bold Italics">Laboratory Tests:</span> The following tests may be helpful in evaluating the HPA-axis suppression:
</p>
<p>Urinary free-cortisol test, ACTH stimulation test
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s13"></a><a name="section-6.4"></a><p></p>
<p class="First"><span class="Bold Italics">Carcinogenesis, Mutagenesis, and Impairment of Fertility:</span> Long-term animal studies have not been performed to evaluate the carcinogenic potential of topical corticosteroids or their effect on fertility.
</p>
<p>Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s14"></a><a name="section-6.5"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy Category C:</span> Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s15"></a><a name="section-6.6"></a><p></p>
<p class="First"><span class="Bold Italics">Nursing Mothers</span>: 
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to 
produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk 
in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s16"></a><a name="section-6.7"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Use:</span><span class="Bold"> Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA-axis suppression and Cushing's syndrome than mature patients because of a higher ratio of skin surface area to body weight.</span></p>
<p>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.
</p>
<p>Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s17"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span> and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s18"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see <span class="Bold"><a href="#s9">PRECAUTIONS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s19"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.
</p>
<p>Occlusive dressings may be a valuable therapeutic adjunct for the management of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or recalcitrant conditions.
</p>
<p>If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s20"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Amcinonide Cream USP, 0.1% (1 mg/g) is supplied as follows:
</p>
<dl>
<dt> 
</dt>
<dd>NDC 0168-0278-15 15 gram tubes
</dd>
<dt> 
</dt>
<dd>NDC 0168-0278-30 30 gram tubes
</dd>
<dt> 
</dt>
<dd>NDC 0168-0278-60 60 gram tubes
</dd>
</dl>
<p>Store at controlled room temperature 15° - 30°C (59° - 86°F)(see USP). DO NOT FREEZE
</p>
<p><span class="Bold">E. FOUGERA &amp; CO.<br></span>
							A division of <br><span class="Bold">Fougera<br></span>PHARMACEUTICALS INC.<br>Melville, New York 11747
</p>
<p>I2278C<br>R08/12<br>#53
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-11"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 15 GRAM TUBE</h1>
<p class="First"><span class="Bold">
						NDC </span>0168-0278-15
						
						</p>
<p><span class="Bold">Fougera</span><span class="Sup">®</span></p>
<p><span class="Bold">AMCINONIDE<br>CREAM USP, 0.1%</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC USE.<br>FOR DERMATOLOGIC USE ONLY.</span></p>
<p><span class="Bold">NET WT 15 grams</span></p>
<p><a name="f02"></a><img alt="15 GRAM TUBE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8aefa477-ac2c-41c8-a807-d24522aed8f0&amp;name=amc03-0003-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s22"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 15 GRAM CARTON</h1>
<p class="First"><span class="Bold">
						NDC </span>0168-0278-15
						
						</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Fougera</span><span class="Sup">®</span></p>
<p><span class="Bold">AMCINONIDE<br>CREAM USP, 0.1%</span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC USE.<br>FOR DERMATOLOGIC USE ONLY.</span></p>
<p><span class="Bold">WARNING:</span> Keep out of<br>reach of children.
						</p>
<p><span class="Bold">NET WT 15 grams</span></p>
<p><a name="f03"></a><img alt="15 GRAM CARTON" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8aefa477-ac2c-41c8-a807-d24522aed8f0&amp;name=amc03-0003-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMCINONIDE 		
					</strong><br><span class="contentTableReg">amcinonide cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0168-0278</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Amcinonide</strong> (Amcinonide) </td>
<td class="formItem">Amcinonide</td>
<td class="formItem">1 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sorbitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl palmitate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0168-0278-15</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0168-0278-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0168-0278-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076065</td>
<td class="formItem">05/15/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>E. Fougera &amp; Co. a division of Fougera Pharmaceuticals Inc.
							(043838424)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5eaae9df-92e8-4c26-890d-54dead7e0ccb</div>
<div>Set id: 8aefa477-ac2c-41c8-a807-d24522aed8f0</div>
<div>Version: 4</div>
<div>Effective Time: 20130708</div>
</div>
</div> <div class="DistributorName">E. Fougera &amp; Co. a division of Fougera Pharmaceuticals Inc.</div></p>
</body></html>
